Saturday 17 October 2026 Export IRWD’s income statement to Excel — free account

Ironwood Pharmaceuticals, Inc.

IRWD Healthcare Drug Manufacturers Specialty & Generic

Ironwood Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $296.2 million, down 15.7% from fiscal 2024. In the quarter to June 2026, revenue grew 32.6%, EPS grew 106.7%, free cash flow grew 486.7% and total debt was flat, each against the same quarter a year earlier.

3.50 0.27 −7.16%

Follow IRWD

Alert me

Market cap: $623.0M
P/E: 4.4×
Fwd P/E: 2.8×
Dividend yield: —
F-score: 5/9
Altman Z: −3.75
Beneish M: −4.20
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 22.62

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	—	1	6	1	—	—	1	1	—	—	—

Insider Ownership 3.23%

Capital & Financial Ratios $m

Market Cap 622.95

Revenue 389.32

Net Income 129.87

Free Cash Flow 185.56

Net Debt 305.87

Current Ratio 6.06

Debt/Equity (2.38)

P/E ratio 4.39

Fwd P/E 2.81

P/S ratio 1.48

P/B ratio 0.00

Past 5Y EPS Growth (25.65%)

This Y EPS Growth 715.56%

Next Y EPS Growth 7.63%

Next Y revenue growth 59.18%

Next 5Y EPS Growth 112.04%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 22.01%

10-year low 10-year high

P/S against its own 10 years 7.67%

10-year low 10-year high

EV/Sales against its own 10 years 7.96%

10-year low 10-year high

EV/FCF against its own 10 years 9.02%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	92	89	215	79
Receivables	129	82	47	113
Inventory	—	—	—	—
Other	—	—	—	—
	233	182	274	199

	2023	2024	2025	Q'26
Payables	8	2	3	1
ST’ Debt	200	—	200	—
Other	—	—	—	—
	276	39	242	33

Compound Annual Growth %

	10y	5y	3y
Sales	7.07%	(5.33%)	(10.32%)
Cash Flow	0.00%	(5.53%)	(22.58%)
Earnings	0.00%	(25.72%)	(48.42%)
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	107	113	—	—	—
’25	41	85	122	48	296
’24	75	94	92	91	351
’23	104	107	114	118	443
’22	98	97	109	107	411
’21	89	104	104	117	414
’20	80	89	103	117	390

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	5	58	—	—	—
’25	20	(15)	48	75	127
’24	45	33	10	15	104
’23	80	35	32	36	183
’22	64	61	69	79	274
’21	74	49	75	65	262
’20	44	20	54	52	169

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	5	58	—	—	—
’25	20	(15)	48	75	127
’24	45	33	10	15	103
’23	80	35	32	36	183
’22	64	61	69	79	274
’21	74	49	75	64	262
’20	42	20	54	51	167

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.24	0.31	—	—	—
’25	(0.23)	0.14	0.23	(0.01)	0.15
’24	(0.03)	(0.01)	0.02	0.01	0.01
’23	0.25	(6.84)	0.09	(0.01)	(6.45)
’22	0.21	0.21	0.28	0.27	0.96
’21	0.25	2.39	0.34	0.25	3.21
’20	0.02	0.16	0.21	0.27	0.66

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	6.16	11.25	7.60	7.91	7.99	8.78	9.73	8.07	3.06	0.53	Analyst estimates 2026–2028 Powerpack
	High	14.15	16.70	17.76	14.10	14.06	14.27	12.95	12.66	15.70	4.78
People
People	Employees	674	730	515	317	232	219	219	267	253	100
	Revenue/emp, $m	0.41	0.41	0.67	1.35	1.68	1.89	1.87	1.66	1.39	2.96
Income, $m
Income, $m	Revenue	274	298	347	428	390	414	411	443	351	296
	Gross margin, %	99.32	93.60	90.55	94.43	99.19	100.00	100.00	100.00	100.00	100.00
	EBT	(82)	(55)	(194)	59	109	201	252	(948)	65	70
	EBT margin, %	(29.83)	(18.41)	(56.01)	13.76	27.95	48.50	61.48	(214.14)	18.55	23.65
	Net income	(82)	(117)	(282)	22	106	528	175	(1,032)	1	24
	Depreciation	11	13	12	6	4	2	1	2	2	2
Per share, $
Per share, $	Revenue	1.89	2.00	2.27	2.75	2.44	2.55	2.66	2.85	2.21	1.83
	Earnings	(0.56)	(0.78)	(1.85)	0.14	0.67	3.26	1.13	(6.45)	0.01	0.15
	Cash flow	(0.18)	(0.68)	(0.46)	0.07	1.06	1.61	1.77	1.18	0.65	0.79
	Capex	(0.72)	(0.02)	0.01	(0.04)	(0.01)	0.00	0.00	0.00	0.00	0.00
	Free cash flow	(0.90)	(0.69)	(0.46)	0.02	1.05	1.61	1.77	1.18	0.65	0.78
	Book value	0.46	0.07	(1.29)	(0.60)	0.39	3.73	4.23	(2.23)	(1.89)	(1.62)
	Shares, m	145	149	153	156	159	162	154	155	159	162
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	17.00	3.58	10.76	0.00	0.00	21.38
	P/S	6.59	6.39	3.82	4.85	4.66	4.57	4.61	4.36	2.01	1.84
	P/B	27.05	193.50	0.00	0.00	28.99	3.12	2.90	0.00	0.00	0.00
	EV/Sales	6.81	6.97	4.51	5.39	4.84	4.21	3.98	5.73	3.98	3.09
	EV/FCF	(62.37)	(20.11)	(22.45)	606.61	11.29	6.66	5.98	13.84	13.54	7.20
Cash, $m
Cash, $m	Operating cash flow	(26)	(101)	(71)	11	169	262	274	183	104	127
	Capex	(104)	(3)	1	(7)	(2)	0	0	0	0	0
	Free cash flow	(130)	(103)	(70)	4	167	262	274	183	103	127
Balance, $m
Balance, $m	Working capital	289	246	147	266	464	584	755	(43)	144	32
	Total debt	373	400	414	409	433	473	399	698	584	585
	Net debt	68	179	239	231	69	(149)	(258)	606	495	369
	Shareholders’ equity	67	10	(196)	(93)	63	606	652	(346)	(301)	(262)
Returns, %
Returns, %	ROA	(12.30)	(17.78)	(60.22)	5.85	22.07	62.68	15.72	(127.54)	0.21	6.42
	ROIC	(24.14)	(5.09)	(218.71)	54.61	67.89	31.74	39.69	(227.77)	29.99	57.33
	ROE	(100.97)	(305.46)	302.77	(14.85)	(693.71)	158.09	27.83	(654.88)	(0.27)	(8.53)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
COLL Collegium Pharmaceutical, Inc.	$754.6M	15.2×	12.5×	+6.32% (above 0%: growing)	n/m	−2.14% (below 0%: shrinking)	55.18%	1.85%	Compare
IRWD Ironwood Pharmaceuticals, Inc.	$623.0M	4.4×	2.8×	+32.62% (above 0%: growing)	+106.67% (above 0%: growing)	+486.70% (above 0%: growing)	100.00%	70.16%
AQST Aquestive Therapeutics, Inc.	$509.6M	— (loss-making)	— (loss-making)	+38.15% (above 0%: growing)	n/m	−20.35% (below 0%: shrinking)	70.93%	(59.51%)	Compare
EVO Evotec AG	$504.4M	— (loss-making)	— (loss-making)	−12.98% (below 0%: shrinking)	n/m	−9,727.20% (below 0%: shrinking)	(1.00%)	(77.50%)	Compare
EOLS Evolus, Inc.	$500.0M	— (loss-making)	— (loss-making)	+21.18% (above 0%: growing)	n/m	+84.90% (above 0%: growing)	68.00%	(5.40%)	Compare
TLRY Tilray Brands, Inc.	$474.4M	— (loss-making)	— (loss-making)	+22.74% (above 0%: growing)	n/m	−36.60% (below 0%: shrinking)	30.14%	(9.35%)	Compare
KMDA Kamada Ltd.	$451.7M	20.4×	— (loss-making)	+22.72% (above 0%: growing)	+23.08% (above 0%: growing)	+165.71% (above 0%: growing)	40.91%	17.32%	Compare
TKNO Alpha Teknova, Inc.	$408.0M	— (loss-making)	— (loss-making)	+18.45% (above 0%: growing)	n/m	+74.18% (above 0%: growing)	40.09%	(23.72%)	Compare
EBS Emergent Biosolutions Inc.	$368.1M	— (loss-making)	— (loss-making)	+66.29% (above 0%: growing)	n/m	−47.68% (below 0%: shrinking)	58.56%	(53.39%)	Compare
Median of peers	$487.2M	—	—	+21.95%	—	−11.24%	48.05%	(16.53%)

All 86 Drug Manufacturers Specialty & Generic stocks →

Ironwood Pharmaceuticals, Inc. (IRWD) key facts

Concern: Ironwood Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $296.2 million, down 15.7% from fiscal 2024.
Ironwood Pharmaceuticals, Inc. (IRWD) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, IRWD traded at $3.50, a market capitalization of $623.0 million.
Return on equity was −8.53% and debt-to-equity -2.38.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −3.75 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.